Sequent Scientific Limited

BSE:512529 Stock Report

Market Cap: ₹44.5b

Sequent Scientific Past Earnings Performance

Past criteria checks 3/6

Sequent Scientific's earnings have been declining at an average annual rate of -54.3%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 3.9% per year. Sequent Scientific's return on equity is 3.7%, and it has net margins of 1.1%.

Key information

-54.3%

Earnings growth rate

-54.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate3.9%
Return on equity3.7%
Net Margin1.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sequent Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:512529 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2414,4941652,5340
30 Jun 2414,267552,4850
31 Mar 2413,697-3592,5490
31 Dec 2313,705-1,2852,5650
30 Sep 2314,212-1,4572,6550
30 Jun 2314,128-1,4102,6160
31 Mar 2314,209-1,2122,6200
31 Dec 2214,380-1862,5330
30 Sep 2214,207742,3270
30 Jun 2214,3362632,3020
31 Mar 2214,1284102,3370
31 Dec 2113,9095292,3220
30 Sep 2113,8797132,3170
30 Jun 2113,8698052,0870
31 Mar 2113,6169541,9130
31 Dec 2013,1539631,7820
30 Sep 2012,7357931,7510
30 Jun 2012,1157941,6950
31 Mar 2011,7926991,6820
31 Dec 1911,6067021,7300
30 Sep 1911,1476291,6700
30 Jun 1910,8225681,5050
31 Mar 1910,3934871,5610
31 Dec 189,9023481,4790
30 Sep 189,4461601,4100
30 Jun 188,904361,3460
31 Mar 188,47891,2270
31 Dec 1710,4572041,4370
30 Sep 1710,3023521,4470
30 Jun 179,9141841,3560
31 Mar 176,836-1131,1500
31 Dec 168,797-3491,3740
30 Sep 167,592-4301,2130
30 Jun 166,652-3259910
31 Mar 166,062-2009040
31 Dec 155,718-8481,3330
30 Sep 155,297-8481,2560
30 Jun 154,789-5351,2360
31 Mar 154,432-6576340
31 Dec 143,779-6765790
30 Sep 143,805-7145290
30 Jun 144,467-1,1254680
31 Mar 143,950-1,1038960

Quality Earnings: 512529 has high quality earnings.

Growing Profit Margin: 512529 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 512529 has become profitable over the past 5 years, growing earnings by -54.3% per year.

Accelerating Growth: 512529 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 512529 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.4%).

Return on Equity

High ROE: 512529's Return on Equity (3.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 01:49
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sequent Scientific Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nikhil ShettyBP Wealth Management Private Limited
null nullIIFL Wealth Management Ltd.